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COMPREHENSIVE REVIEW
Paving the Way Toward Complex Blood-Brain
Barrier Models Using Pluripotent Stem Cells
Karin Lauschke,1,2 Lise Frederiksen,3 and Vanessa Jane Hall4
A tissue with great need to be modeled in vitro is the blood-brain barrier (BBB). The BBB is a tight barrier that
covers all blood vessels in the brain and separates the brain microenvironment from the blood system. It consists
of three cell types [neurovascular unit (NVU)] that contribute to the unique tightness and selective permeability
of the BBB and has been shown to be disrupted in many diseases and brain disorders, such as vascular
dementia, stroke, multiple sclerosis, and Alzheimer’s disease. Given the progress that pluripotent stem cells
(PSCs) have made in the past two decades, it is now possible to produce many cell types from the BBB and
even partially recapitulate this complex tissue in vitro. In this review, we summarize the most recent devel-
opments in PSC differentiation and modeling of the BBB. We also suggest how patient-specific human-induced
PSCs could be used to model BBB dysfunction in the future. Lastly, we provide perspectives on how to improve
production of the BBB in vitro, for example by improving pericyte differentiation protocols and by better
modeling the NVU in the dish.
Keywords: blood-brain barrier, induced pluripotent stem cell, in vitro model, neurodegenerative disease,
scaffold, bioprinting
Introduction
The blood-brain barrier (BBB) is one of the three se-lective permeable barriers that protects the central ner-
vous system from the peripheral system and forms at the
interface of the microvasculature (arterioles, capillaries, and
venules) of the brain and the brain parenchyma. The role of
the BBB is multifactorial and includes diffusion of nutrients,
removal of metabolites from the brain, preventing the entry of
neurotoxic proteins into the brain and regulating leukocyte
permeation [1]. It consists of a single layer of brain micro-
vascular endothelial cells (BMECs), which line the blood
vessels and interact closely with an outer encapsulating layer
of pericytes, as well as astrocytes, neurons, and microglia.
Together, these cell types form a complex cellular and
physical interaction with surrounding cells and physical
forces from the blood stream that regulate the BBB’s per-
meable properties [2].
The BBB has been extensively studied, as it is an im-
portant barrier to permeabilize in the case of delivering
drugs to the brain. However, it is affected and undergoes
breakdown during normal aging [3], as well as in several
brain disorders, including stroke [4] and epilepsy [5]. It is
also perturbed in many neurodegenerative diseases, such as
amyotrophic lateral sclerosis (ALS) [6], Parkinson’s disease
(PD) [7], Huntington’s disease (HD) [8], vascular dementia
[9], and Alzheimer’s disease (AD) [10–13].
Modeling the BBB in a dish is a particularly attractive
way to study the molecular mechanisms that may be in-
volved in its breakdown; however, it is also useful for de-
termining the transport of novel drugs through the barrier,
before clinical trial testing. In vitro modeling traditionally
uses cultured BMECs from varying species; however, these
have limitations, including species differences [14] and low
barrier tightness due to the monoculture of BMECs [15].
Building a complex BBB with its various cell types
generated from human pluripotent stem cells (hPSCs)
would be the ultimate in vitro model of the BBB and
would be useful for determining mechanisms underlying
disease/disorder. However, to date, there are only a limited
number of studies that attempt to produce the BBB from
PSCs. Here, we outline the current progress in the field and
where the field is heading. We provide a background on
the anatomical and molecular features of the BBB, as well
as a brief overview of the in vitro cellular models in
widespread use, before focusing on the PSC-derived BBB
1National Food Institute and 2Department of Micro- and Nanotechnology, Technical University of Denmark, Kongens Lyngby,
Denmark.
3Faculty of Health and Medical Sciences, University of Copenhagen, København N, Denmark.
4Department of Veterinary and Animal Sciences, Faculty of Health and Medical Sciences, University of Copenhagen, Frederiksberg C,
Denmark.
STEM CELLS AND DEVELOPMENT
Volume 26, Number 12, 2017
 Mary Ann Liebert, Inc.
DOI: 10.1089/scd.2017.0003
857
D
ow
nl
oa
de
d 
by
 D
an
ish
 T
ec
hn
ic
al
 U
ni
ve
rs
ity
 fr
om
 o
nl
in
e.
lie
be
rtp
ub
.c
om
 a
t 0
7/
11
/1
7.
 F
or
 p
er
so
na
l u
se
 o
nl
y.
research. We then consider how protocols could be im-
proved by advancing cellular differentiation protocols, by
using different matrices, both chemical and mechanical,
and more complex cell culture models.
Cell types of the BBB
The monolayer of BMECs together with the encapsu-
lating pericytes are ensheathed in an extracellular matrix
(ECM), termed the basement membrane, and astrocytes
project their end-feet toward this basement membrane
(Fig. 1) [16]. The ratio between the endothelial cells (ECs),
astrocytes, and pericytes in vivo is estimated to be 1:5:1
[17]. Other glia, such as oligodendrocytes and microglia,
as well as neurons, also interact with these cells. A fric-
tional force from the flowing blood along the vasculature
system on the BMECs forms what is known as shear stress,
one of the important physical factors controlling BBB
permeability [16] (Fig. 1).
Brain microvascular endothelial cells. BMECs are spe-
cialized epithelial cells that form the physical neurovascular
barrier through their effective tight junctions (TJs) (Fig. 2).
BMECs are enclosed by pericytes with an estimated cov-
erage of 30% [18], and both cell types lie on ECM proteins.
Importantly, the pericytes and astrocytes regulate the
BMECs and thereby BBB tightness, although it is only the
pericytes that directly contact the BMECs.
The BMEC’s TJs consist of a complex of proteins, in-
cluding occludin and claudin, which span the membranes of
two adjacent BMECs that hold them close together [16].
These proteins are often used as markers for barrier for-
mation of BMECs. The formation of TJs occurs after the
formation of another cell junction in the BMECs, the ad-
herens junctions [19]. Similar to TJs, adherens junctions
consist of a complex of proteins, including VE-cadherin and
E-cadherin proteins, which span the membrane of two
neighboring BMECs and are also useful markers for BBB
tightness [16,20] (Fig. 2).
Pericytes. Pericytes exhibit multipotent properties that
are similar to mesenchymal stem cells, and they have been
demonstrated to differentiate into both osteoblasts and adi-
pocytes. In the BBB, the absence of pericytes increases BBB
permeability [21]. This is believed to be regulated by the
secretion of various mediator molecules that affect trans-
porter and TJ protein expression in the BMECs [22]. Peri-
cytes also regulate the basement membrane by expressing
and secreting components of the ECM, and they help direct
astrocyte end-feet to the basement membrane [23]. Pericytes
have a unique synergistic interaction with BMECs, due to
their close contact, but further roles have yet to be identified
due to the difficulty in isolating this cell type and also since
it does not have a unique expression profile.
Astrocytes. The BMECs and pericytes are ensheathed by
astrocytes, which contact the ECM with their end-feet,
which has an estimated coverage of *99% [18]. Astrocytes
secrete mediator molecules from their end-feet to stimulate
both pericytes and BMECs. Some of these secreted mediator
molecules affect the expression of TJ and transporter pro-
teins, whereas others, such as prostaglandin E or nitric ox-
ide, stimulate pericytes to contract or relax to regulate blood
flow [23]. Astrocytes are also activated as a result of in-
flammation and secrete pro-inflammatory mediators, which
increases BBB permeability and leukocyte infiltration [24].
Transport through the BBB
The BBB facilitates passage across the BMECs in five
alternate ways: (1) Paracellular transport occurs between the
BMEC plasma cell membranes, through the TJs, allowing
for transport of water-soluble agents. This is regulated by
the TJs, restricts the diffusion of ions and other polar sub-
stances through the BBB, and blocks the passage of mac-
romolecules [25] (Fig. 2). Importantly, the BMECs are
highly polarized and contain a luminal and an abluminal
side, which differ in lipid composition and transport pro-
teins. This allows for transcellular passage of lipid-soluble
FIG. 1. The blood-brain barrier in vivo. The BBB is a tight and selective barrier that protects the brain from the peripheral
system, which is permitted by the cell types of the NVU. BMECs form the epithelium of the blood vessels in the brain and
are covered by pericytes, which cover about 30% of the endothelial cells. Both cell types contribute to and are unsheathed in
the basement membrane. Astrocytes attach to the basement membrane with their end-feet, and neurons are in close
proximity to the other cell types. Together, these cells form the NVU. BBB, blood-brain barrier; BMEC, brain micro-
vascular endothelial cells; NVU, neurovascular unit.
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agents that can enter and pass through the BMECs by dif-
fusion. (2) Proteins and nutrients may pass through the
BMECs by specific solute carriers, such as the glucose
transporter 1 (GLUT-1) [26]. A list of the varying BBB
transporters can be reviewed [27]. (3) There are also efflux
transporters such as P-glycoprotein (P-gp) and multidrug
resistance protein 2 (MRP2) that actively transport a variety
of molecules from the brain back into the bloodstream [16].
(4) Receptor-mediated transcytosis constitutes another
mechanism that BMECs use to carry insulin and transferrin
across the cell membrane. (5) Lastly, adsorptive transcytosis
shuttles albumin and other plasma proteins directly through
BMECs (Fig. 2).
Regardless of all these different transport mechanisms, the
BMECs have a very limited permeability, which is particu-
larly important, since it repels neurotoxic agents, but this also
creates a challenge for finding drugs that can be delivered to
the brain. The restriction of ions leads to a transendothelial
electrical resistance (TEER), which can be measured exper-
imentally and is a key parameter for assessing BBB tightness.
The physiological TEER value in humans is estimated to be
around 5,000 Ocm2 (for further details, see Methods Used to
Detect BBB Tightness section).
Endothelial monoculture and co-culture models
BMEC monocultures were the first in vitro BBB models
developed (Fig. 3A). In the simplest setting, the cells are
grown on a microporous filter membrane that separates a dish
into two compartments, an apical and a basolateral side of the
filter. In this model, BMECs have been used from various
origins, that is, mouse, rat, pig, cow, monkey, or human (for a
review of the models from different origins, see Helms et al.
[27]). In the case of human BMECs, the availability of human
primary BMECs is particularly restricted due to limited
available post-mortem tissues. Therefore, immortalized human
adult BMEC lines have been developed, for example, the
widely used human cerebral endothelial cell line (hCMEC/D3)
[28] (for review, see Weksler et al. [29]). However, BMEC
lines in monoculture de-differentiate and downregulate many
genes involved in cell-cell adhesion and maturation compared
with primary BMECs [30–32]. Low TJ tightness leads to un-
physiologically low TEER values of maximum 300 Ocm2
[29], potentially due to the lack of stimulating factors from
other cell types [15]. To accommodate the other cell types of
the neurovascular unit (NVU) in one setup, several co-culture
models have been developed:
First, the co-culture of BMECs with astrocytes is reported
in several different models (Fig. 3C). The experimental
setup can vary, with the BMECs cultured on the upper side
of a porous filter and (i) the astrocytes are grown on the
lower side of the transwell filter (Fig. 3C), (ii) the astrocytes
are grown on the bottom of the well (Fig. 3C), or (iii)
BMECS are cultured with astrocyte-conditioned medium
(set up as in Fig. 3A) [15].
Second, the addition of pericytes to BMECs alone, and
to BMEC and astrocyte co-cultures, has also been at-
tempted (Fig. 3B, D). Hatherell et al. describe a triple
culture of human ECs, astrocytes, and pericytes in varying
settings, as depicted in Fig. 3D [33]. One interesting study
that included pericytes in its co-culture model detected
reasonable TEER values of a maximum of 400 Ocm2,
when astrocytes were cultured on the bottom of the
transwell, pericytes on the lower side of the filter, and ECs
on the upper side of the filter [34]. This first triple-culture
model also revealed expression of several marker proteins
in the BMECs and a good correlation with in vivo per-
meability of characterized compounds [35].
Despite these positive outcomes, several studies have
revealed opposing outcomes when triple cultures have been
attempted [33,34,36,37]. Another very recent study has also
systematically compared 10 different setups of mono- and
co-cultures and found profound effects on the TEER value
when ECs are co-cultured with both primary pericytes and
human-induced pluripotent stem cells (hiPSC) derived
neural stem cells (NSCs), or with primary pericytes,
FIG. 2. Transport mechanisms through the BBB. The BMECs are connected by TJs and adherens junctions that facilitate
the transcellular tightness. TJs consist of a complex of proteins, including occludin and claudin, whereas the main adherens
junctions are cadherins. This tight connection between adjacent endothelial cells restricts paracellular transport, thereby
making the BBB impermeable for small molecules and ions, which can be measured by transendothelial resistance.
Transcellular transport is possible for lipid-soluble agents that pass through the cells by diffusion. Efflux transporters in the
luminal membrane compartment, such as P-glycoproteins, actively transport molecules back into the vascular lumen.
Specific receptors shuttle signaling molecules through the cells, and solute carriers transport nutrients from the lumen into
the abluminal (parenchymal) side. Also, adsorptive transcytosis facilitates transport through the barrier. These pathways
facilitate selective permeability and can be measured by the transport of proteins such as dextran or lucifer yellow. TJ, tight
junction.
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astrocytes, and hiPSC-NSCs [38]. This study further sup-
ports the beneficial effects of pericytes on BBB tightness.
Lastly, the inclusion of neural progenitor cells (NPCs) into
BMEC cultures (Fig. 3E) has been shown to increase BBB
tightness in vitro [39]. This outcome has led to the further
development of a co-culture model, including BMECs, NPCs
(which develop into neurons), and astrocytes, which resulted
in a BBB, reaching TEER values of a maximum of 250 Ocm2
[39]. An overview of the current in vitro BBB models based
on human BMECs can be found in Table 1.
Generation and Characterization
of In Vitro BBB Models
Methods used to detect BBB tightness
To assess the integrity of the barrier in in vitro models,
qualitative and quantitative methods have been established and
will be presented here briefly: The characteristics of the TJ
proteins, occludin, Zonula occludens 1 (ZO-1), and Zonula
occludens 2 (ZO-2) can be imaged with freeze-fraction electron
microscopy (FFEM) [40]. The functional tightness can be
validated by the flux of molecules with different molecular
weights such as dextran, lucifer yellow, sodium fluorescein,
glucose, insulin, or mannitol. Another useful control is sucrose
because it is BBB impermeable, hydrophilic and there is no
brain-specific uptake mechanism [41]. To test for the expres-
sion of specific receptors or transporter proteins, these can also
be selectively inhibited and the flux can be measured [42,43]. A
widely used standard assay for permeability is the measure-
ment of the TEER, which is given in Ocm2. For a concise
review on TEER measurement techniques for in vitro models,
we recommend reading the following article [44]. Importantly,
it should be noted that the TEER can differ greatly depending
on the experimental setup [44], and, therefore, independent
studies cannot be directly compared.
PSC differentiation into NVU cell types
The recent advances in PSC technologies have opened
new avenues toward generating more complex in vitro BBB
FIG. 3. In vitro models of the BBB based on human BMECs. In the transwell system, several settings and combinations of
the cell types of the NVU have been published: (A) Monoculture of BMECs grown on the upper side of the transwell filter.
(B) Co-culture of BMECs grown on the upper side of the filter with pericytes on the bottom of the well. (C) Co-culture of
BMECs grown on the upper side of the filter with astrocytes either on the bottom of the well or on the lower side of
the transwell filter. (D) In the triple culture setting, BMECs are cultured with pericytes and astrocytes on the bottom of the
transwell or the lower side of the filter. (E) BMECs on the upper side of the filter are first cultured with pericytes on the
bottom of the well. After 24 h, BMECs are cultured together with astrocytes and neurons, derived from NPCs, on the bottom
of the well. (F) Co-culture of BMECs with PSC-derived pericytes, astrocytes, and neurons for 5 days, followed by BMEC
maintenance on the upper side of the filter and astrocyte growth on the bottom of the transwell. NPC, neural progenitor cells.
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models, which are much closer to the in vivo situation in
humans compared with the BMEC monocultures. Here, we
discuss the progress in differentiation of the three main cell
types of the NVU from PSCs that are summarized briefly in
Table 2.
Brain microvascular endothelial cells. In general, ECs line
the lumen of the microvasculature in many organs and there
are profound tissue-specific characteristics of each EC type.
In the case of BMECs, these are characterized by generating
a high TEER and by releasing specific angiogenic factors
[45]. It is, therefore, crucial to define markers for BMECs
and to prove the BMEC identity on differentiation from
PSCs. VE-cadherin and PECAM-1 are generally accepted
markers for all ECs; however, the large heterogeneity of
ECs among tissues hinders the use of one single marker for
BMECs [46]. Therefore, a combination of tissue-specific
markers and expressed proteins is needed to define BMECs
as a unique EC, which should be combined with pheno-
typical assays, such as angiogenic or vasculogenic assays
[47]. Therefore, we classify here that ECs are produced from
PSCs rather than BMECs, unless proved otherwise by the
authors.
Numerous protocols exist to generate ECs from hPSCs.
These include spontaneous differentiation from embryoid
bodies (EBs) [48] that can be improved by addition of
growth factors for mesoderm induction, including basic fi-
broblast growth factor (bFGF) and insulin-like growth factor
(IGF) together with vascular endothelial growth factor
(VEGF) [49] or bone morphogenetic protein 4 (BMP4) [47].
Also, co-culturing of hPSCs [50] or hiPSCs [51] with the
mouse bone marrow stromal cell line OP9 has yielded ECs.
Improved protocols that lead to the derivation of BBB-
specific BMECs include co-culturing with glioma cell lines
[52], NPCs [53], or astrocytes [54].
These protocols rely on the same hypothesis, that co-
culture with neural cells pushes ECs toward a brain identity.
The study by Minami et al. on co-culturing with a glioma
cell line used CD34 and CD144 (VE-cadherin) as markers
for ECs, which were sorted from the population and ana-
lyzed for CD31 (PECAM) and Von Willebrand factor to
identify BMECs. This was further verified by detecting
claudin, occludin, and ZO-1 expression, as well as by ob-
serving vascular-like structures in Matrigel and uptake of
acetylated low-density lipoprotein [52]. However, these
cells alone yielded a TEER of only 55 Ocm2, indicating a
barrier tightness that is far from representative of the in vivo
BMEC [52]. This indicated that induction by co-culturing
with neural cultures is not sufficient for inducing BMEC
properties, possibly due to the importance of factors se-
creted and/or mechanical interactions that pericytes and
astrocytes have on BMECs.
In 2012, Lippmann et al. reported the first hiPSC-derived
BMECs with BBB properties that could be produced with an
efficiency of >60% [42]. These cells were characterized by
GLUT-1 and PECAM-1 expression, and their BBB identity
was verified by staining for claudin-5, occludin, and VE-
cadherin. The authors attempted to mimic in vivo BBB de-
velopment, where endothelial and neuronal lineages form at
the same time. To this end, they kept hiPSCs in uncondi-
tioned medium without pluripotency factors, to allow for the
differentiation of both neural and endothelial progenitors.
After 5–7 days, this mixed population was switched to a
medium that selectively stimulated EC proliferation for a
further 1–2 days. The BMECs were then purified from the
NPCs on selective collagen IV matrices, yielding a pure
BMEC population (PECAM-1+, GLUT-1+ cells). This pop-
ulation expressed BBB markers such as occludin and claudin-
5, and it created a TEER of a maximum of 175 Ocm2. On co-
culture with primary rat astrocytes grown on the bottom of
the transwell, the monolayer of BMECs reached 412 Ocm2.
This was further enhanced by optimizing the seeding
density to create a more complete and an even monolayer
that increased the TEER value further to 1,450 Ocm2 [42].
In a follow-up study, the differentiation of hiPSCs was
improved toward more physiological BMECs by the addi-
tion of retinoic acid (RA) to the EC medium. This led to
increased expression of VE-cadherin, occludin, and claudin-
5, as well as TEER values of more than 5,000 Ocm2. Al-
though the differentiation efficiency was not affected by the
addition of RA, total cell proliferation was increased,
leading to a higher number of BMECs [43,55]. RA is se-
creted by radial glia during brain development and is crucial
for the development of a tight BBB during mouse devel-
opment as well as in BMEC lines [56]. Within cells, it is
bound by retinol-binding protein that is expressed in
BMECs in vivo and also binds to the nuclear receptor
STRA6 [57]. STRA6 expression is also upregulated during
BMEC differentiation in vitro [42].
Recently, Katt et al. differentiated an hiPSC line into
BMECs by using the Lippmann protocol with RA-
supplemented EC medium, but they altered the timing of two
steps in the protocol. The same markers were used as in the
Lippmann study. Differentiation of hiPSC culture was initiated
by changing to undefined medium without the pluripotency
factor bFGF at 70% confluence. When the BMEC morphology
was most prevalent (at day 6), the medium was changed to EC
medium containing RA. This approach yielded a differentiation
efficiency of an impressive 93% and a TEER of 2,000Ocm2 [58].
Another study by Appelt-Menzel et al. reproduced the differ-
entiation of BMECs with the Lippmann protocol and retrieved
TEER values of a maximum of 2,500Ocm2 in a co-culture model
with NSCs, astrocytes, and pericytes [38]. Importantly, FFEM
revealed that the TJ proteins showed a similar morphology as
reported on brain ECs in vivo, showing that morphologically
relevant BMECs can be retrieved from hiPSCs [38].
In conclusion, the co-culture with neural cell types is
promising to retrieve ECs with brain characteristics. How-
ever, the most critical step toward generating functional
BMECs, which generate high TEER values, from stem cell
sources is the use of a combination of astrocytes and EC
medium supplemented with RA. Nevertheless, despite the
apparent efficiency of the Lippmann protocol, there are no
reports to date from other laboratories that can reproduce the
reported TEER values of 5,000 Ocm2.
Pericytes. Differentiation of PSCs into pericytes has not
been as successful as differentiation into BMECs due to the
lack of knowledge on the factors that produce pericytes
in vivo. Furthermore, many pericyte markers are also ex-
pressed by ECs, mesenchymal cells, and smooth muscle
cells, with the exception of the platelet-derived growth
factor receptor (PDGFRb), and, therefore, characterization
of pericytes in a dish is difficult. Pericytes have been created
from PSCs by spontaneous differentiation followed by
screening for pericyte-lineage markers and subsequent
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isolation of perivascular precursors. Differentiation into
vascular cell types is enhanced by low oxygen conditions,
which can be used to produce early vascular cells that can be
further matured into pericytes and ECs [59,60]. A recent
study found that increasing cell seeding density for spon-
taneous differentiation of EBs from PSCs resulted in cells
with a mesenchymal-like morphology, which were suppos-
edly perivascular precursors [61]. However, the cells were
unable to differentiate into either osteoblasts or adipocytes,
which is a hallmark feature of pericytes [61].
Another group applied a similar approach and continu-
ously analyzed and isolated cells with pericyte-lineage
markers during differentiation, without the use of selective
media. After 7 weeks, isolated cells expressed several peri-
cyte markers, including PDGFRb, and showed morphological
features of human placenta pericytes that could differentiate
into both adipogenic and osteogenic tissue [62]. Orlova et al.
induced PSCs directly into the mesodermal lineage by in-
ducing SMAD2/3 and WNT activation, followed by vascular
specification by supplementing VEGF and inhibiting trans-
forming growth factor-b. Cells expressing EC markers were
isolated and expanded, and after 3 days pericytes appeared as a
homogenous population of cells that were positive for pericyte
markers, including PDGFRb. The study reported a pericyte
differentiation efficiency of 30% defined by PDGFRb-positive
cells [63,64]. Despite this progress, the differentiation of
pericytes is still far from optimal and requires further im-
provement of differentiation protocols to increase the per-
centage of cells, which we discuss in the next section on
improvements of BBB production in vitro.
Astrocytes. Contrary to the other BBB cell types, astrocyte
differentiation from PSCs is well established and astrocytes
have been successfully differentiated since 2011 [65], al-
though the initial protocols were relatively long (6 months)
[65,66]. However, a more recent protocol for producing as-
trocytes was successful after only 5 weeks. It employs an
initial differentiation step into NPCs followed by activation of
the JAK/STAT and SMAD pathways to activate the astrocyte-
specific glial fibrillary acidic protein (GFAP) gene. This pro-
tocol resulted in an efficiency of 60%–80%, defined by GFAP
[67]. Another study by Mormone et al. used initial SMAD
inhibition in their protocol followed by JAK/STAT activation
and reported the generation of 60% GFAP-positive astrocytes.
To enhance the purity of the astrocytes, the cells were then
magnetic-activated cell sorted by using the astrocyte marker
A2B5, which resulted in a purity of 95% GFAP-positive as-
trocytes [68,69].
Complex in vitro PSC-derived BBB models
To date, only two laboratories have published multicellular
in vitro models of the BBB from hiPSCs. Lippmann et al.
gained human BMECs from hiPSCs as discussed earlier
[42,43], and they combined these in a multicellular BBB model
with human neurons and astrocytes generated from NPCs [43].
hiPSC-derived BMECs were co-cultured first with primary
human pericytes for 24 h and, subsequently, with a mixture of
astrocytes and neurons differentiated from primary human
NPCs (Fig. 3E). This optimal culture condition led to TEER
values of more than 5,000 Ocm2, whereas culture with only
pericytes reached slightly lower levels of 4,500 Ocm2 [43].
Culture without pericytes only reached half of the TEER
values, supporting the importance of pericytes in BBB tightness.
Intriguingly, this group advanced their model by employing
astrocytes, neurons, and BMECs from the same hiPSC source
[70]. hiPSC-derived BMECs were co-cultured with neurons and
astrocytes, which were produced through EZ spheres from the
same hiPSC source. The monoculture of hiPSC-derived BMECs
reached a TEER value of 200Ocm2, whereas the co-culture with
the isogenic neurons and astrocytes (in a ratio 1:3) elevated the
TEER to nearly 800Ocm2 [70]. This was slightly lower than in
the previously reported co-culture with NPC-derived astrocytes
and neurons (1,450 Ocm2) [42]. However, the isogenic co-
culture model did not include pericytes, which might increase
the TEER values, as previously presented in the model with
pericyte priming (up to 5,000 Ocm2) [43].
The second laboratory published an interesting approach,
deriving all four cell types of the BBB from hiPSC (Fig. 3F)
[71]. The group previously characterized that cyclic AMP
efficiently supports the differentiation of hiPSC toward ECs
[72–75]. However, as in the other studies, co-culture with
pericytes, astrocytes, and neurons is still necessary to induce
BMEC hallmarks [71]. Strikingly, for their co-culture, they
used hiPSC-derived neurons, astrocytes, and pericytes. The
EC and pericytes were differentiated together by inducing
first mesoderm formation and then the vascular endothelial
lineage, followed by sorting ECs and pericytes by combined
cell surface markers. Astrocytes and neurons were derived
from EBs over a period of 120 days.
Having generated all four cell types, the researchers
combined them into one culture for 5 days to induce BMEC
hallmarks in the ECs. However, not all four cell types were
transferred to a transwell BBB model. Only the BMECs and
astrocytes were transferred (Fig. 3F). Unfortunately, TEER
values of only 100 Ocm2 were achieved [71], which might
potentially be increased by the further addition of pericytes and
neurons into the transwell system. The beneficial effect of
pericytes was also found in a systematic comparison of dif-
ferent multicellular models, in which hiPSC-BMECs were co-
cultured with hiPSC-derived or primary neuronal cells and
pericytes [38].
These studies highlight many advantages of hPSCs to
create in vitro models of the BBB: First, BMEC can be
obtained easily in high quantities due to efficient differen-
tiation protocols. Second, the co-differentiation experiments
with NPCs [42,43], the isogenic co-culture model [76], and
the fully PSC-derived model [71] showed that, in principle,
all BBB cell types can be made from the same stem cell
source. Third, the obtained BMECs showed extremely high
TEER values that have never been generated with any other
BMEC source. The PSC-derived BMECs have also been
shown to respond well in artificially invoked stress condi-
tions, which might be valuable for some assays. For ex-
ample, PSC-derived BMECs have been reported to respond
more physiologically to hypoxia than the hCMEC/D3 cell
line [77]. Most importantly, however, is that a combination
of co-culturing with varying (primary) cell sources appears
to be a significant advantage of improving hiPSC-derived
BMEC BBB tightness [38].
There have also been studies describing the production of
BBB from other stem cell sources, that is, cord blood-
derived stem cells in a co-culture with either pericytes [78]
or astrocytes [54]. However, we believe that hiPSCs repre-
sent a superior stem cell source since: (1) hiPSCs are a
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renewable source with very little ethical concerns attached;
(2) hiPSCs are easy to manufacture, and numerous hiPSC
lines are available; and (3) patient-derived hiPSCs might
recapitulate the disease phenotype in vitro.
What do we expect from an ideal BBB model?
An important step in generating a more physiologically
relevant model of the human BBB is to ask: Which criteria
should an ideal model fulfil? Although the criteria might
differ depending on the experimental question, the model
should mimic the in vivo BBB as close as possible. We
highlight four points that could be adopted for estimating the
value of an in vitro BBB model [79]: (1) reproducibility of a
restrictive solute permeability (measured by the TEER and
tracer flux); (2) functional expression of transporters (as-
sessed by the efflux ratio of known molecules as well as
specific inhibitors of known transporters); (3) physiologically
realistic architecture containing polarity, that is, containing a
luminal and an abluminal side, gross cell dimensions, surface
area of interactions, as well as complexity of TJs (measured
by light, fluorescence, and transmission electron microscopy
or FFEM); and (4) easy to culture with acceptable cell pro-
liferation rates and continuous growth [15]. In Table 1, we
rate the previously published PSC-derived BBB according to
how well they may fulfil these criteria and how physiologi-
cally relevant they are (Table 1).
Using PSCs for modeling neurovascular disease
To date, several in vitro and in vivo models of neurovas-
cular diseases exist, particularly from the mouse. However,
there is a need for more human models that recapitulate the
in vivo disease state. hPSC-derived neural models have par-
ticularly flourished in recent years, since they can recapitulate
different neural cell types readily. However, models of the
diseased BBB are needed, since it is affected in many neu-
rological diseases. Moreover, there is a need to include the
BBB together with PSC-derived neural cells since these
models could help to more closely recapitulate the physio-
logical and physical interactions that might lead to the de-
tection of disease phenotypes that have not been recapitulated
in vitro yet, for example, neuronal death that might only be
induced by BBB breakdown [80].
Disease-causing mutations often cause phenotypes in only
certain cell types, or regions, as, for example, in ALS, where
only motor neurons and glial cells are affected, which has been
successfully recapitulated with ALS patient-derived hiPSCs
[81]. Also, other neurological syndromes are highly cell-type
specific, such as AD, PD, and HD. Selective loss of neurons in
these diseases leads to impaired cognitive and mobile function,
depending on the site and severity of neural loss [82]. Not long
after iPSCs were first produced came the first publication of
iPSCs generated from patients with neurofibromatosis type 1
disease [83]. Since then, several proof-of-principle studies
have shown that both sporadic and genetic diseases can be
modeled with hiPSCs from patients [84].
For example, PD has been modeled with hiPSC-derived do-
paminergic neurons carrying mutations such as a triplication of
synuclein-alpha (SNCA) [85] or the most common mutation in
LRRK2 [86], both of which lead to increased levels of a-
synuclein. Another study found altered ERK signaling in derived
dopaminergic neurons that, when repressed, was able to reverse a
certain disease pathology, such as sensitivity to oxidative stress
and neurite shortening [87]. Also, proteasome dysfunction, ox-
idative stress, and increased expression ofa-synuclein have been
observed in PARK2 mutant hiPSC-derived neurons [88]; how-
ever, no Lewy body formation or neurodegeneration has been
recapitulated in hiPSC-derived dopaminergic neurons. Also, AD
[89,90] and HD [91] have been mimicked in the dish and re-
produced important disease phenotypes. However, none of the
neurons die in culture, as seen in AD patients [8,92]. Recently, it
was reported that healthy neurons from hiPSC degenerate if
transplanted in PD model mouse brains, suggesting that amyloid
plaques from the diseased environment are responsible for neural
degeneration [93].
Intriguingly, the permeability of the BBB has been shown
to be altered in these diseases, although it is not clear whether
this is a cause or a consequence of the disease [94,95]. BBB-
related mutations, as, for example, in the ABCB1 gene, en-
coding the P-gp efflux transporter expressed in BMECs, have
been associated with PD [96,97]. Similarly, BBB breakdown
has also been seen in AD patients [98]. Furthermore, im-
portant BMEC transporters such as GLUT-1 and P-gp have
been found with impaired function in AD patients [10,99].
Remarkably, the APOE protein, of which isoform 4
(APOE4) is a major risk factor for AD, is expressed in the end-
feet of astrocytes [100]. Deletion of APOE in mice, in fact,
leads to BBB breakdown, as displayed by increased leakage of
dye into the brain of APOE-deficient mice compared with
wild-type mice [101], and this difference increases with age
[102]. Moreover, replacement of the endogenous APOE gene
in mice with the human AD risk factor isoform APOE4 im-
pairs BBB function [103]. Later, these results were confirmed
by multiphoton microscopy of fluorescence-conjugated dex-
tran, which was widely distributed in the brains of mice ex-
pressing deletion mutants or APOE4 [95]. This elegant study
further revealed that fluorescently labeled neurotoxins accu-
mulate in neurons of these mice, suggesting an increased
neurotoxin exposure through the leaky BBB.
Importantly, at the time of BBB breakdown (2 weeks of age),
neuronal activity measured by voltage-sensitive dyes was the
same in mutant and wild-type mice, whereas it was dramatically
decreased in mutant mice at 4 months of age [95]. This sub-
stantiates the theory that BBB breakdown precedes neuronal
changes and underpins the in vivo relevance of a tight BBB.
These studies highlight the possibility that BBB dysfunc-
tion might be causal or an early feature of AD, and that the
BBB is, therefore, important to be included in an in vitro
disease model. Also, for HD, the disease hallmark, that is,
accumulation of the mutant Huntington (mhtt) protein in
various cell types of the brain, has also been found in cells of
the BBB in both mouse models and post-mortem tissue from
HD patients [8]. Importantly, protein levels of the TJ-proteins
claudin-5 and occludin were lower in mouse models of HD
[8] and AD [95], and this correlated with a larger intracellular
space between adjacent BMECs in HD mice [8].
To summarize, hiPSC have been successfully employed
to model neurovascular diseases, although not all disease
phenotypes have been recapitulated in vitro. Emerging
evidence suggests that BBB disintegrity is involved in these
diseases, and, therefore, the inclusion of BBB cell types in
these models might potentially aid in fully exposing all
disease phenotypes. Retrieval of the BBB cell types from
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hiPSCs is particularly attractive since the neurovascular cell
types cannot be easily derived from human patients, unless
under surgery, for example, if a tumor is excised. Therefore,
a promising alternative is to generate each cell type from the
BBB by using hiPSCs derived from the patient.
Future Considerations for Improving
BBB Production In Vitro
For future BBB models, one should consider the tre-
mendous improvements in cell culture and tissue engineer-
ing that also enhance the differentiation of stem cells. Stem
cell fate is influenced exclusively by its extracellular che-
mical and physical environment, which is termed the ‘‘stem
cell niche,’’ a concept first proposed in 1978 by Schofield
[104]. In vivo, this is also a place of residence for the stem
cells, in addition to its surrounding microenvironment that
controls their differentiation and self-renewal [105]. Stem
cells, therefore, require a mechanical substrate to grow on,
as well as soluble factors that regulate their fate. Important
factors of the niche in vivo may be secreted from other cells,
the ECM, paracrine factors, and metabolites [106]. Many of
these characteristics require recapitulation in vitro, and this
can partly be achieved by using innovative (bio-) materials
and microfabrication techniques to modify the culture en-
vironment systematically [107].
All the current PSC-derived BBB models lack an im-
portant feature, which is blood flow. Blood flow is an im-
portant physiological factor influencing the BBB in vivo, by
activating mechanosensors on the apical surface of the ep-
ithelium [108]. This physical stimulus has been proved to
regulate EC differentiation and adhesion [109] as well as
cell division, apoptosis, cell migration, and polarization of
the epithelium [110]. It stimulates TJ expression and cell
adhesion in primary and immortalized BMECs [110] such as
ZO-1, claudin-5 [111,112], and the efflux transporter P-gp
[112]. Drug transporters and metabolizing enzymes are ex-
pressed at higher levels under shear stress induced by blood
flow [113]. Also, increased in vitro shear stress has been
demonstrated to improve permeability values and to induce
differentiation of ESCs into endothelial-like cells [114,115].
Side-by-side comparisons with bovine EC lines cultured
with or without shear stress of 4 dynes/cm2 in hollow fibers
showed an increase in TEER from 60 Ocm2 to more than
600 Ocm2 [116]. This was confirmed in a recent study on rat
primary BMECs, where TEER values rose fourfold to 1,300
Ocm2. In this study, cells were grown in a three-dimensional
(3D) microfluidic device directly on a collagen bed, with
medium flow applied through a medium channel on the cells
[117]. The increased barrier tightening is believed to involve
the adherens junction protein VE-cadherin, by signaling the
shear stress response to occludin and changing TJ protein
expression and organization [111].
Nevertheless, the effects of shear stress on multicellular
BBB models and on iPSC-derived ECs have yet to be analyzed.
Historically, flow has been created in hollow fibers by a
computer-controlled pump to reach values between 5 and 23
dynes/cm2, which is similar to in vivo values [110]. However,
there are drawbacks of the hollow fiber system. These include
its unsuitability for high-throughput screening and that the cells
cannot be analyzed morphologically in the tube. Therefore,
alternative ways to employ shear stress are required to intro-
duce flow of the medium in perfusion culture dishes during or
after differentiation, potentially through use of microfluidic
systems. For example, flow might be employed through inlet
and outlet channels that push liquid through a hydrogel res-
ervoir in which the cells are cultured [118]. Alternatively, cells
might be grown on a membrane within a microfluidic device
with a flow channel on top of the cells, as described by Booth
and Kim in 2014 [119]. Importantly, shear stress might act on
only one side of the ECs (apical or basal), and the flow can be
used to transport nutrients and waste products as well.
Three-dimensional culturing
It has been observed that 3D scaffolds provide physiologi-
cally more relevant models and are closer to in vivo models than
conventional two-dimensional (2D) cell cultures [120]. Three-
dimensional scaffolds support the differentiation of stem cells
into desired cell types and tissues, for example, in culturing
neurons and epithelial cells. For example, a remarkable step in
the development of brain organoids was accomplished with the
use of Matrigel as a supportive 3D matrix [121].
Besides the choice of scaffold material, several possibil-
ities exist for the 3D setup of the BBB depending on the
purpose of the model. For drug delivery and safety studies,
the major focus lies on permeability of the barrier, and the
developed models, therefore, must contain two compart-
ments that are separated by a filter membrane. On the
contrary, for phenotypical or molecular analysis, this is not
necessary and simpler models are sufficient.
For example, a multicellular spheroidal BBB model arranged
all cell types of the BBB in direct contact without the need of a
surrounding scaffold; primary human BMECs, pericytes, and
astrocytes self-assembled spontaneously into a tube-like struc-
ture [122]. Although the barrier tightness and therefore func-
tionality of this BBB model could not be assessed, it is still
fascinating that the cells assembled spontaneously into layers
with BMECs forming an outer monolayer, astrocytes accumu-
lating in the lumen of the spheroid, and pericytes forming a layer
between the other two cell types [122].
Lastly, 3D models without two compartments can still be
used to study the uptake of molecules into BMECs or other
cell types of the BBB. Although this gives no information
on permeability values measured by TEER, it might give an
indication as to whether a substance can enter or cross the
BMECs. For example, one study assessed the uptake of gold
nanoparticles into BMECs or into 3D cultured astrocytes,
which were covered by a layer of BMECS, by electron
microscopy [123].
To introduce compartmentalization in 3D cultures, an elegant
approach is to embed human astrocytes and pericytes into col-
lagen type I and inject this mixture around needles into a chip, as
developed by Tourovskaia et al. in 2014 [124]. After gelation, the
needles are removed, leaving hollow channels in which
hBMECs are injected to form a monolayer covering the walls of
the channels. Tourovskaia et al. showed that in their setup, the
pericytes and astrocytes in the collagen matrix grew in close
contact with the BMEC monolayer, mimicking the in vivo sit-
uation closely. This led to a tight barrier, as assessed by imaging
fluorescently labeled sucrose and dextran [124]. However, no
TEER measurements were possible in this setting and the ex-
pression of TJ or transporter proteins was not analyzed, giving
very little information on the physiology of the BBB model.
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Another strongly expanding field is the use of hollow
fiber tubes to mimic the cerebrovasculature in 3D, and to
facilitate co-culture of cells as well as flow conditions in the
tube [125,126]. However, the measurement of TEER and
permeability requires more sophisticated setups that are
compatible with the fiber architecture, compared with sim-
ple transwell systems. Nevertheless, several studies showed
the feasibility of a commercially available hollow fiber
system that includes electrodes covering the hollow fibers to
measure the TEER. In this system, human BMECs were co-
cultured with human astrocyte cell lines in a hollow fiber
and TEER values greater than 700 Ocm2 were measured
[127]. Also, within the area of microfabrication, several
attempts to mimic the BBB have been pursued. This tech-
nology is reviewed in detail by Helm et al. [128].
Lastly, we envision further development of the classical
transwell system (Fig. 3) by adding 3D neural tissues in
either compartment. This may enhance the maturation of
BMECs and the formation of physiological BBB charac-
teristics, such as TJ formation and transporter expression.
This could potentially be accomplished by 3D printing of
the cells (bioprinting) to enhance an even distribution of
cells across the scaffold. The feasibility of this approach has
been recently demonstrated with NPCs embedded in a
polyurethane (PU) dispersion [129]. The cell-laden disper-
sion was 3D printed into several layers of fibers and main-
tained at 37C, and the viability of the cells was proved after
2 days of culture [129]. Three-dimensional bioprinting with
all cell types of the BBB could also potentially arrange all
cell types in the same compartment, overcoming the limi-
tations of spatial separation by a transwell filter. Importantly,
this would also facilitate cell-cell interactions, which improves
stem cell differentiation [130,131]. This might lead to forma-
tion of more physiological morphology and BBB tightness
(Fig. 4A). We envision these techniques would further advance
the recently developed BBB models, although this currently
lies at the very edge of our technological abilities.
Progress in bioengineering of scaffolds
Introduction of better cell culture matrices and improved
ECM substrates into these BBB models might help to im-
prove culture conditions and may enhance the physiological
matrix stiffness and shear stress [132]. In recent years, ad-
vanced scaffolds and biomimetic materials have been de-
veloped that facilitate a more controlled microenvironment
FIG. 4. Future considerations for improving BBB production from stem cell sources in vitro. Developments that might
improve the traditional transwell filter systems. (A) Arranging all cell types of the NVU in the same compartment,
potentially by 3D bioprinting (left). Through enhanced cell-cell interactions, this might lead to a more physiological cell
morphology and BBB characteristics (right). (B) Novel materials might replace traditional filter membranes to reduce the
physical separation between co-cultured cells. Biodegradable materials to produce the filter membrane might be used as
well, and eventually degrade over time, to enable formation of more physiological-like barriers. (C) Cells might be
encapsulated in 3D gels, such as hydrogels, that mimic the in vivo extracellular matrix more closely (left) and enhance cell
morphology and barrier tightness during culture (right). 3D, three dimensional.
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in vitro [106]. We envision several applications where novel
biomaterials might be applied:
First, novel materials might help to overcome certain
limitations of the materials used for the filter membranes in
transwell in vitro BBB models. One limitation in traditional
transwell filters is the filter membrane with 10–20mm thick-
ness, which well exceeds the size of the basal lamina and,
therefore, acts as a physical barrier between the cells seeded
on either side of the filter. These filter membranes could be
replaced by membranes made from novel biomaterials, for
example, biodegradable polymers, to provide an initial sub-
strate for adherence, which, eventually, degrades later in
culture to produce a more physiological boundary (Fig. 4B).
Second, novel scaffolds for 3D culturing or improved
differentiation of hiPSC could be developed. Today, the
most abundantly used 3D scaffold is Matrigel, which has
been recently shown to improve BMEC monolayer barrier
tightness [133]. Matrigel is commonly used as a scaffold to
culture and differentiate hPSCs into BMECs, which are then
seeded onto permeable transwell filter membranes that are
coated with collagen and fibronectin [42,43].
Alternative scaffolds for 3D cultures can be constructed
by the use of various polymers, hydrogels, silicons, and
many more [106]. The choice of material depends greatly on
the application and cell type, and the chosen material should
mimic the in vivo supportive tissue. A special need in BBB
modeling is that the scaffolds should enable the measure-
ment of TEER values and, therefore, enable free movement
of ions [134]. For example, collagen type I has been used in
BBB models to embed the BBB cell types in a 3D gel
[124,135]. Also, hyaluronic acid is often used in engineering
brain tissue because it is also found in brain ECM and might
be a suitable candidate to aid BBB models [134].
Polymers with many promising features for use in BBB
modeling are hydrogels, since they mimic the ECM closely, are
biocompatible and easy to fabricate. Various microfabrication
techniques are available to produce 3D hydrogel scaffolds for
tissue engineering [106]. Hydrogels can be produced from
naturally derived polymers such as collagen, gelatin, algenate,
or Matrigel, or synthetic polymers such as polylactic acid or
PU. The latter has recently been used in bioengineering due to
its good physical properties and biocompatibility [106].
Synthetic polymers bear the advantage of being chemi-
cally defined, reproducible, and modifiable in regards to
their physical and chemical properties. However, these
polymers are usually formed based on cross-linking chem-
istry, which is toxic for cells and, therefore, a problem if the
cells are to be encapsulated in the hydrogel [136]. Recently,
a technique was developed to produce hydrogels from PU
dispersions without the need of cross-linking, which can,
therefore, be used to encapsulate cells [129]. This technique
might enable the wrapping of all three BBB cell types in the
same scaffold, thereby improving the maturation and de-
velopment of a physiological barrier (Fig. 4C).
Another advantage of hydrogels is that they can be loaded
with chemicals, mimicking ECM-bound regulatory factors
in vivo [129,137]. The ECM is known to provide important
cues on cells both through its structure and its release of stim-
ulating factors [138]. The use of more physiologically relevant
ECM proteins is, therefore, important to consider, and the in-
corporation of additional ECM components might help to im-
prove the functional properties and maturation of BMECs in
vitro [139]. For example, ECM ligands secreted by ECs include
not only fibronectin and collagen IV but also laminin, SPARC,
Nidogen-1, and Agrin [140]. Recently, an elegant study
showed that the composition and assembly of endogenous
ECMs contribute to BBB formation in vitro [133].
Improvement of the scaffolds and where the cells are
deposited could help to increase the contact between the
different cell types as well as improve BMEC polarity,
physiological stiffness, and the transport of metabolites and
soluble regulators. Therefore, future BBB models could
contain scaffolds that are loaded with ECM factors or use
conditioned scaffolds that are similar to conditioned me-
dium. Another important factor is the rigidity and elasticity
of the scaffold. Bone cells need a rigid environment,
whereas neurovascular cells require more elastic environ-
ments that are similar to the in vivo situation. Here, the
composition of synthetic hydrogels could be varied to adjust
the stiffness of the scaffold to the needs of the cells [136].
Future perspectives for creation of PSC-derived
BBB models
There are several aspects that could be applied to im-
prove differentiation of BMECs from PSCs. The cell
density before the differentiation of PSCs has an effect on
the resulting yield and TEER, and the optimal seeding
density varies depending on the PSC line used [141]. Un-
defined sources such as Matrigel and feeder cells provide
inconsistency, and alternatives of defined origin should be
considered. The addition of RA has proved to significantly
enhance barrier tightness as well as cell proliferation,
leading to high numbers of BMECs [43]. Although the
protocols for differentiating neurons and astrocytes are
well established, and BMECs can be differentiated with a
high efficiency, only few protocols exist for pericytes. This
is partially due to a lack of pericyte markers; however,
even without a definitive marker, pericytes can be char-
acterized by their ability to form stable vascular tubes to-
gether with ECs [142]. This feature might be exploited, and
also eventually co-culture of both cell types might improve
the differentiation and maturation of pericytes.
The BBB models produced from PSC do not contain aged
cells. Importantly, differentiated PSCs are more represen-
tative of cells from young, rather than aged individuals. This
may be an issue if it is important to study diseases that have
BBB breakdown in aged people.
The production of cell types from young individuals in
vitro is likely due to the rejuvenation of cells after iPSC
reprogramming, which results in increased telomere length
[143,144] and ESC-like mitochondria in the undifferentiated
iPSCs [145]. Therefore, it could be important to mimic old
age in the dish by accelerating the aging of hiPSC-derived
cells. To this end, the differentiated cells can be exposed to
stress paradigms, including toxins or other compounds that
lead to oxidative or mitochondrial stress [146].
One intriguing method that has been used for aged iPSC-
derived cells in vitro is to overexpress progerin, a truncated
isoform of laminin A, which is associated with premature
aging. Overexpression in neurons that were differentiated
from PD-derived iPSCs revealed age-related disease pheno-
types that were otherwise not detected in vitro [147]. Based
on these findings, it has been proposed that accelerating the
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aging of iPSC-derived cells could help to elucidate aging
mechanisms coupled with the disease [146].
Conclusion
In conclusion, the greatest potential of PSCs for biomedical
research lies in their ability to form complex tissues with phys-
iologically relevant characteristics. PSCs have been able to yield
several cell types of the BBB, which is the important vascular
interface between the brain and the blood, and it is affected in
many neurodegenerative diseases and blood disorders. To date,
the BBB has been modeled in relatively simple 2D cultures that
are composed of monolayers of BMECs, yielding few physio-
logical characteristics. However, the production of a more
FIG. 5. Future outlook for use of advanced BBB models for treatment of neurodegenerative diseases. Patients with neurovascular
diseases donate their cells, for example, fibroblasts, for reprogramming into pluripotent stem cells. From these, all cell types of the
NVU may be generated, that is, BMECs, pericytes, astrocytes, and neurons, to build advanced in vitro models of the BBB. These
models can be used for studying the molecular mechanisms of the disease or for testing and developing novel drugs. This might also
be useful for personalized medicine, that is, to find the best treatment for the respective patient. From such studies, novel treatments
might evolve to improve life quality and survival of the patient. BMEC, brain microvascular endothelial cell; BBB, blood-brain
barrier; NVU, neurovascular units.
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complex BBB, which contains several cell types of the NVU,
would certainly recapitulate the physiological tightness and
permeability better. The use of PSCs in creating this more
complex BBB has been initiated, and great success in recreating
the tightness has already been achieved. However, more com-
plex cultures, the advances in biomaterials, and 3D culturing will
definitely help to lead this field into even more advanced in vitro
models of the BBB. Importantly, use of patient-specific hiPSCs
to create the BBB in the future will help to determine more about
the mechanisms related to BBB breakdown and provide more
insight into disease mechanisms that might ultimately lead to the
development of new drugs (Fig. 5).
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